These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 8252745)

  • 1. Plasma 19-hydroxyandrostenedione is elevated in patients with high renin essential hypertension.
    Sekihara H; Yonemitsu K; Yazaki Y
    Clin Endocrinol (Oxf); 1993 Nov; 39(5):557-60. PubMed ID: 8252745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin II induces the release of 19-hydroxyandrostenedione in man.
    Sekihara H; Torii R; Osawa Y; Takaku F
    J Clin Endocrinol Metab; 1985 Aug; 61(2):291-6. PubMed ID: 2989318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 19-Hydroxyandrostenedione: a potent hypertensinogenic steroid in man.
    Sekihara H
    J Steroid Biochem; 1983 Jul; 19(1A):353-8. PubMed ID: 6310235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 19-hydroxyandrostenedione and 6 beta-hydroxyandrostenedione: new steroids regulated by the renin-angiotensin system in man.
    Sekihara H
    J Steroid Biochem; 1984 Jan; 20(1):383-5. PubMed ID: 6708521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 6 beta-Hydroxyandrostenedione: evidence for a new hypertensinogenic agent.
    Sekihara H
    Clin Exp Hypertens A; 1983; 5(1):1-9. PubMed ID: 6339119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 19-hydroxyandrostenedione as a new hypertensinogenic agent.
    Sekihara H
    J Steroid Biochem; 1982 Feb; 16(2):329-31. PubMed ID: 7043093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 19-Hydroxyandrostenedione: evidence for a new class of sodium-retaining and hypertensinogenic steroids.
    Sekihara H
    Endocrinology; 1983 Sep; 113(3):1141-8. PubMed ID: 6347666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma 19-hydroxy-androstenedione (19-OH-A) in essential hypertension.
    Tosti-Croce C; Rinaldi R; Massaria M; Lomurno A; Felicioli T; Sciarra F
    Clin Exp Hypertens A; 1992; 14(6):1083-94. PubMed ID: 1330385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low plasma 19-hydroxyandrostenedione levels in patients with aldosterone-producing adenoma.
    Morita H; Mune T; Yasuda K; Yamakita N; Miyazaki S; Miura K
    Endocr J; 1993 Feb; 40(1):89-97. PubMed ID: 7951501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for age-related change in plasma 19-hydroxyandrostenedione.
    Higuchi K; Ogo A; Maki T; Haji M; Takayanagi R; Ohashi M; Nawata H; Kato K; Ibayashi H
    Endocrinol Jpn; 1989 Dec; 36(6):881-5. PubMed ID: 2561277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated plasma 19-hydroxyandrostenedione levels in Cushing's disease: stimulation with ACTH and inhibition with metyrapone.
    Mune T; Morita H; Yasuda K; Murayama M; Yamakita N; Miura K
    Clin Endocrinol (Oxf); 1993 Mar; 38(3):265-72. PubMed ID: 8384536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 19-Hydroxyandrostenedione amplifies the hypertensive action of mineralocorticoids in rats.
    Sekihara H; Yazaki Y; Kojima T
    J Endocrinol; 1993 Jul; 138(1):31-40. PubMed ID: 7852890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secretory regulation of 19-hydroxyandrostenedione in normal man.
    Morita H; Mune T; Yasuda K; Mercado-Asis LB; Murayama M; Yamakita N; Miyazaki S; Miura K
    Endocrinol Jpn; 1992 Oct; 39(5):431-8. PubMed ID: 1478184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha-human atrial natriuretic polypeptide inhibits 19-hydroxy-androstenedione secretion by human adrenal cells.
    Higuchi K; Nawata H; Kato K; Ibayashi H
    Horm Metab Res; 1989 Feb; 21(2):92-5. PubMed ID: 2542147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for primary aldosteronism--normal ranges for aldosterone and renin in three South African population groups.
    Rayner BL; Myers JE; Opie LH; Trinder YA; Davidson JS
    S Afr Med J; 2001 Jul; 91(7):594-9. PubMed ID: 11544978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid increase of mineralocorticoids after furosemide in low-renin essential hypertension: evidence for 18-hydroxycorticosterone to be a better marker than aldosterone.
    Witzgall H; Thayil G; Weber PC
    Klin Wochenschr; 1982 Aug; 60(16):847-52. PubMed ID: 6752560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mineralocorticoid secretion in essential hypertension with normal and low plasma renin activity.
    Messerli FH; Kuchel O; Nowaczynski W; Seth K; Honda M; Kubo S; Boucher R; Tolis G; Genest J
    Circulation; 1976 Mar; 53(3):406-10. PubMed ID: 1248073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of the hypertensinogenic action of 19-hydroxyandrostenedione by aromatase inhibitor, delta 1-testololactone.
    Sekihara H; Yonemitsu K; Takaku F
    Endocrinology; 1987 Dec; 121(6):1931-6. PubMed ID: 3678133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Relation of atrial natriuretic peptide, the renin-angiotensin-aldosterone system and kinin system in hypertensive and normotensive youngsters with or without a family history of essential arterial hypertension].
    Musca A; Ferri C; Cammerella I; Onofri R; Tani S; Santucci A
    Medicina (Firenze); 1989; 9(2):167-72. PubMed ID: 2530412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Excess of mineralocorticoids in essential hypertension: clinical-diagnostic approach].
    Cortés P; Fardella C; Oestreicher E; Gac H; Mosso L; Soto J; Foradori A; Claverie X; Ahuad J; Montero J
    Rev Med Chil; 2000 Sep; 128(9):955-61. PubMed ID: 11349499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.